Concept
Version 5
Created by Boundless
Immunotherapy for Cancer
Structure of GD2
GD2 is a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastomas and melanomas, with highly restricted expression on normal tissues, principally to the cerebellum and peripheral nerves in humans. The relatively tumor-specific expression of GD2 makes it a suitable target for immunotherapy with monoclonal antibodies or with artificial T-cell receptors.
Source
Boundless vets and curates high-quality, openly licensed content from around the Internet. This particular resource used the following sources: